Abstract:Objects Polymorphism of genes for dopamine D 2 receptor promoter (DRD2P), 5 HT 2A receptor (5 HT 2A ), catechol o methyltransferase (COMT), and monoamine oxidase A type (MAO A) were examined synchronously for exploring the genetic factors related to schizophrenia Methods Forty three pedigrees with at least two siblings affected schizophrenia according to ICD 10 criteria and biological parents alive were recruited The Chinese versions of the Diagnosis interview for Genetics Study (DIGS) and the Family Interview for Genetics Study (FIGS) were fulfilled Genomic DNA was isolated from lymphocytes by a standard procedure After polymerase chain reaction (PCR), the cleavage was done Then the genotypes were read by 1% agarose gel electrophoresis with 100 bp DNA ladder The chi square test, correlation analyses, and the transmission disequilibrium test (TDT) were employed Results (1) No significantly different distribution between groups of parents, non affected siblings and affected siblings was found, when polymorphism of DRD2P, 5 HT 2A , and COMT were analyzed But significantly different distribution of genotype or allele was found, when comparing with 941A/941G and 941G/941G genotypes of MAO A between groups of parents and non affected siblings, or parents and affected siblings No significant difference, however, was found between the groups of non affected siblings and affected siblings (2) 941G allele of MAO A was transmitted significantly more to affected siblings from parents (χ 2= 5 33, P 0 05, OR =3 32,95% CI : 1 58 6 99) And 941A allele of MAO A and -241A allele of gene for DRD2 promoter were transmitted significantly more to non affected siblings from parents (χ 2=4 84, P 0 05, OR =6 04, 95% CI : 2 01 18 69) But both T102G polymorphism of 5 HT 2A and Val108Met polymorphism of COMT were not found to have significant transmission disequilibrium ( P 0 05) (3) Significant relationship was found between genotype of gene for DRD2P promoter, or COMT, or MAO A and schizophrenic clinical features, but not genotype of T102C polymorphism of 5 HT 2A Conclusions (1) Our results support hypothesis of DA dysfunction in the etiology of schizophrenia (2) From this study, we infer that there are relationships between these candidate genes and schizophrenia at different degree That is MAO ADRD2PCOMT5 HT 2A .

Polymorphisms in Dopaminergic Genes in Schizophrenia and Their Implications in Motor Deficits and Antipsychotic Treatment

The Relationship Between Drd2 Gene Polymorphisms (c957t and C939t) and Schizophrenia: A Meta-Analysis

Pharacogenetic Effects of Dopamine Transporter Gene Polymorphisms on Response to Chlorpromazine and Clozapine and on Extrapyramidal Syndrome in Schizophrenia

Morphological Changes in Gray Matter Volume Correlate with Catechol-O-methyl Transferase Gene Val158Met Polymorphism in First-Episode Treatment-Naïve Patients with Schizophrenia

An Association Study Between Dopamine D1 Receptor Gene Polymorphisms and the Risk of Schizophrenia.

Schizophrenia in the genetic era: a review from development history, clinical features and genomic research approaches to insights of susceptibility genes

Advances in Molecular Genetics of Schizophrenia

Dopaminergic Epistases in Schizophrenia

Genetic Polymorphism in Catechol‐o‐methyltransferase Associated with the Functional Connectivity of Frontostriatal Circuits in First Episode Schizophrenia Patients

Modulation on Glutamic Pathway of Frontal-Striatum-Thalamus by Rs11146020 and Rs3813296 Gene Polymorphism in First-Episode Negative Schizophrenia

Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean Cohorts.

Synaptotagmin-11 Deficiency Mediates Schizophrenia-Like Behaviors in Mice Via Dopamine Over-Transmission

An Association Study Between Genetic Polymorphisms in Functional Regions of Five Genes and the Risk of Schizophrenia

Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases

Pharmacogenetics of Treatment in First-Episode Schizophrenia: D3 and 5-HT2C Receptor Polymorphisms Separately Associate with Positive and Negative Symptom Response

Progress in the Studies on the Molecular Genetics of Schizophrenia

Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction

Dopamine signaling enriched striatal gene set predicts striatal dopamine synthesis and physiological activity in vivo

Aberrant glycosylation in schizophrenia: insights into pathophysiological mechanisms and therapeutic potentials

The Relationships Between Four Candidate Functional Genes and Schizophrenia

Association Study of an SNP Combination Pattern in the Dopaminergic Pathway in Paranoid Schizophrenia: a Novel Strategy for Complex Disorders